The estimated Net Worth of Gail J Maderis is at least $95.9 mil dollars as of 12 August 2022. Gail Maderis owns over 25,204 units of Novabay Pharmaceuticals Inc stock worth over $95,860 and over the last 14 years Gail sold NBY stock worth over $0.
Gail has made over 3 trades of the Novabay Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Gail bought 25,204 units of NBY stock worth $17,895 on 12 August 2022.
The largest trade Gail's ever made was buying 174,796 units of Novabay Pharmaceuticals Inc stock on 9 August 2022 worth over $117,113. On average, Gail trades about 7,713 units every 99 days since 2010. As of 12 August 2022 Gail still owns at least 200,000 units of Novabay Pharmaceuticals Inc stock.
You can see the complete history of Gail Maderis stock trades at the bottom of the page.
Gail's mailing address filed with the SEC is C/O DURECT CORPORATION, 10260 BUBB ROAD, CUPERTINO, CA, 95014.
Over the last 18 years, insiders at Novabay Pharmaceuticals Inc have traded over $3,799,939 worth of Novabay Pharmaceuticals Inc stock and bought 24,568,662 units worth $26,237,091 . The most active insiders traders include Pharma (Singapore) Pte. Ltd..., Pioneer Pharma Holdings Ltd... y Pharma (Hong Kong) Co Ltd P.... On average, Novabay Pharmaceuticals Inc executives and independent directors trade stock every 57 days with the average trade being worth of $127,779. The most recent stock trade was executed by Paul E. Freiman on 11 May 2023, trading 858 units of NBY stock currently worth $411.
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Novabay Pharmaceuticals Inc executives and other stock owners filed with the SEC include: